A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

A Prospective Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00292409

Enrollment

400

Registered

2006-02-16

Start date

2005-03-31

Completion date

2007-11-30

Last updated

2013-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia and Schizoaffective Disorder

Brief summary

The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.

Interventions

DRUGAripiprazole

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* diagnosis of schizophrenia or schizoaffective disorder being treated as outpatients,no response to past antipsychotic treatment and patients who symptoms are notoptimally controlled defined as CGI- S\<7

Exclusion criteria

* pregnant or breastfeeding,patients at risk for committing suicide,diagnosis of mood disorders, delirium, dementia and other cognitive disorders,patients treatment resistant to otherantipyschotic medications and treatment with a long acting psychotic in which the last dose was within 3 months of treatment phase

Design outcomes

Primary

Measure	Time frame
Clinical Global Impression-Improvement at endpoint	—

Secondary

Measure	Time frame
Clinical Global Impression scale	—
Investigator's Assessment Questionnaire	—
Patient preference of medication at endpoint	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026